# OnCo record borderline-resectable-pdac (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/borderline-resectable-pdac/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "borderline-resectable-pdac" ;
  schema:name "Borderline resectable pancreatic ductal adenocarcinoma"@en ;
  schema:alternateName "Borderline resectable pancreatic cancer"@en, "BRPC"@en, "Marginally resectable pancreatic cancer"@en ;
  schema:description "Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."@en ;
  schema:url <https://onco.cc/cancers/borderline-resectable-pdac/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pancreatic_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Pancreatic_cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455> ;
  onco:tag "subtype-page", "gastrointestinal" ;
  onco:related <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/locally-advanced-pdac/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/cancers/kras-g12c-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/mr-linac/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/pdac-organoid-pharmacotyping/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/brca/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/autogene-cevumeran/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/>, <https://onco.cc/companies/biontech/> ;
  onco:pathways <https://onco.cc/pathways/pancreatic-cancer-signalling/>, <https://onco.cc/pathways/caf-activation-desmoplasia/> ;
  onco:terms <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/sbrt-term/>, <https://onco.cc/terms/resection-margins/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/locally-advanced/>, <https://onco.cc/terms/ctdna/> ;
  onco:trials <https://onco.cc/trials/preopanc/>, <https://onco.cc/trials/prodige-24/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/trials/nct02843945/> ;
  onco:people <https://onco.cc/people/marc-besselink/>, <https://onco.cc/people/theodore-hong/>, <https://onco.cc/people/albert-koong/>, <https://onco.cc/people/richard-schulick/>, <https://onco.cc/people/jurgen-weitz/>, <https://onco.cc/people/eileen-oreilly/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-conroy-folfirinox-pancreatic-nejm-2011/> ;
  onco:pipeline <https://onco.cc/trials/nct07252232/>, <https://onco.cc/trials/nct02843945/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/ideas/idea-ras-inhibitor-neoadjuvant-pdac/>, <https://onco.cc/technologies/mr-linac/>, <https://onco.cc/technologies/pdac-organoid-pharmacotyping/>, <https://onco.cc/ideas/idea-tr2-organoid-coclinical-arms/> ;
  onco:standardOfCare <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/mr-linac/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/resection-margins/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/nalirifox/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/technologies/biliary-stenting-drainage/> .